Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Biomarkers, Tumor | 33 | 2016 | 461 | 1.370 |
Why?
|
Myelodysplastic Syndromes | 11 | 2014 | 75 | 1.210 |
Why?
|
Racemases and Epimerases | 15 | 2006 | 24 | 1.190 |
Why?
|
Adenocarcinoma | 20 | 2014 | 323 | 1.100 |
Why?
|
Prostatic Neoplasms | 15 | 2006 | 339 | 0.920 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 39 | 0.910 |
Why?
|
RNA-Binding Proteins | 13 | 2014 | 384 | 0.860 |
Why?
|
Immunohistochemistry | 28 | 2016 | 846 | 0.830 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 9 | 2016 | 65 | 0.730 |
Why?
|
Herpesvirus 4, Human | 11 | 2016 | 178 | 0.700 |
Why?
|
Multiple Myeloma | 2 | 2022 | 325 | 0.650 |
Why?
|
Bone Marrow | 15 | 2014 | 177 | 0.560 |
Why?
|
Neoplasm Proteins | 9 | 2012 | 277 | 0.550 |
Why?
|
Biopsy, Needle | 8 | 2006 | 132 | 0.540 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2016 | 152 | 0.510 |
Why?
|
Hodgkin Disease | 3 | 2013 | 55 | 0.470 |
Why?
|
Humans | 143 | 2024 | 59282 | 0.470 |
Why?
|
Mutation | 13 | 2024 | 2452 | 0.470 |
Why?
|
Graft vs Host Disease | 3 | 2013 | 105 | 0.430 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 15 | 0.430 |
Why?
|
Male | 94 | 2024 | 27727 | 0.420 |
Why?
|
Clonal Evolution | 1 | 2013 | 3 | 0.420 |
Why?
|
Diabetes Mellitus, Experimental | 8 | 2000 | 190 | 0.420 |
Why?
|
Bone Marrow Transplantation | 2 | 2013 | 138 | 0.410 |
Why?
|
Aged, 80 and over | 29 | 2024 | 5128 | 0.400 |
Why?
|
Killer Cells, Natural | 12 | 2010 | 215 | 0.390 |
Why?
|
Female | 82 | 2024 | 30695 | 0.380 |
Why?
|
Middle Aged | 50 | 2024 | 16310 | 0.380 |
Why?
|
Lymphoma, B-Cell | 5 | 2016 | 59 | 0.380 |
Why?
|
Bone Marrow Diseases | 2 | 2008 | 14 | 0.380 |
Why?
|
Lymphoproliferative Disorders | 6 | 2012 | 38 | 0.380 |
Why?
|
Antibodies, Monoclonal | 21 | 2006 | 837 | 0.370 |
Why?
|
Carcinoma | 5 | 2006 | 115 | 0.370 |
Why?
|
T-Lymphocytes | 17 | 2012 | 983 | 0.360 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 1999 | 50 | 0.350 |
Why?
|
Islets of Langerhans | 7 | 2007 | 271 | 0.350 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2018 | 167 | 0.350 |
Why?
|
Aged | 45 | 2024 | 13412 | 0.350 |
Why?
|
Precancerous Conditions | 4 | 2014 | 70 | 0.340 |
Why?
|
Carcinoma, Renal Cell | 4 | 2018 | 83 | 0.340 |
Why?
|
Kidney Neoplasms | 4 | 2018 | 126 | 0.330 |
Why?
|
Colonic Neoplasms | 6 | 2003 | 215 | 0.320 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2010 | 46 | 0.310 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2008 | 3 | 0.310 |
Why?
|
Prognosis | 15 | 2016 | 1599 | 0.310 |
Why?
|
Lymphocytes | 11 | 2008 | 190 | 0.310 |
Why?
|
Eukaryotic Initiation Factor-2 | 4 | 2008 | 12 | 0.300 |
Why?
|
Rats | 31 | 2009 | 1909 | 0.300 |
Why?
|
Alveolitis, Extrinsic Allergic | 1 | 2008 | 15 | 0.290 |
Why?
|
Adult | 40 | 2024 | 15663 | 0.290 |
Why?
|
Histocompatibility Antigens | 10 | 1994 | 107 | 0.290 |
Why?
|
Rats, Inbred Strains | 9 | 2009 | 150 | 0.290 |
Why?
|
B-Lymphocytes | 7 | 2016 | 549 | 0.290 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 2007 | 2 | 0.280 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2011 | 135 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2018 | 262 | 0.280 |
Why?
|
Myeloproliferative Disorders | 4 | 2014 | 15 | 0.270 |
Why?
|
DNA-Binding Proteins | 4 | 2024 | 1151 | 0.270 |
Why?
|
Diabetes Mellitus, Type 1 | 9 | 2009 | 605 | 0.270 |
Why?
|
Prostate | 6 | 2006 | 65 | 0.260 |
Why?
|
Neoplasm Staging | 9 | 2016 | 452 | 0.260 |
Why?
|
Lymphoma | 7 | 2012 | 99 | 0.260 |
Why?
|
Melanoma | 4 | 2014 | 329 | 0.250 |
Why?
|
Immunoenzyme Techniques | 16 | 2011 | 107 | 0.250 |
Why?
|
Dioxygenases | 2 | 2024 | 25 | 0.250 |
Why?
|
Receptors, Antigen, B-Cell | 7 | 1988 | 58 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 475 | 0.240 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2016 | 71 | 0.240 |
Why?
|
Membrane Proteins | 7 | 2010 | 846 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 32 | 0.230 |
Why?
|
Tumor Suppressor Protein p53 | 6 | 2016 | 289 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2016 | 96 | 0.230 |
Why?
|
Cytoskeletal Proteins | 3 | 2010 | 196 | 0.230 |
Why?
|
Immunoglobulin lambda-Chains | 3 | 2022 | 10 | 0.230 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2014 | 49 | 0.220 |
Why?
|
Sensitivity and Specificity | 12 | 2016 | 1093 | 0.220 |
Why?
|
Epstein-Barr Virus Infections | 4 | 2013 | 89 | 0.220 |
Why?
|
Macrophages | 6 | 2011 | 1000 | 0.220 |
Why?
|
Phenotype | 13 | 2016 | 1136 | 0.220 |
Why?
|
Immunoglobulin kappa-Chains | 2 | 2022 | 9 | 0.220 |
Why?
|
Cytoskeleton | 6 | 1988 | 137 | 0.210 |
Why?
|
Nevus | 2 | 2014 | 18 | 0.210 |
Why?
|
Membrane Glycoproteins | 6 | 2011 | 660 | 0.210 |
Why?
|
Cytosine | 2 | 2014 | 31 | 0.210 |
Why?
|
Bone Marrow Cells | 8 | 2009 | 231 | 0.210 |
Why?
|
Peptide Initiation Factors | 2 | 2001 | 31 | 0.210 |
Why?
|
Rats, Inbred BB | 5 | 1994 | 134 | 0.200 |
Why?
|
Radiation Tolerance | 4 | 2016 | 49 | 0.200 |
Why?
|
Animals | 54 | 2016 | 19601 | 0.200 |
Why?
|
Lung Neoplasms | 5 | 2014 | 582 | 0.200 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2013 | 10 | 0.200 |
Why?
|
Epigenesis, Genetic | 3 | 2016 | 357 | 0.200 |
Why?
|
Immunologic Capping | 7 | 1983 | 10 | 0.190 |
Why?
|
Flow Cytometry | 7 | 2009 | 639 | 0.190 |
Why?
|
Intestinal Mucosa | 5 | 2010 | 224 | 0.190 |
Why?
|
Neoplasms | 7 | 2016 | 1240 | 0.190 |
Why?
|
5-Methylcytosine | 3 | 2016 | 20 | 0.190 |
Why?
|
Uterine Cervical Dysplasia | 2 | 2011 | 28 | 0.190 |
Why?
|
Proto-Oncogene Proteins | 5 | 2024 | 318 | 0.190 |
Why?
|
Survival Analysis | 9 | 2018 | 555 | 0.180 |
Why?
|
Spleen | 16 | 2012 | 480 | 0.180 |
Why?
|
T-Lymphocyte Subsets | 4 | 2008 | 244 | 0.180 |
Why?
|
Pancreatic Neoplasms | 3 | 2010 | 331 | 0.170 |
Why?
|
Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2014 | 406 | 0.170 |
Why?
|
Leukocytosis | 1 | 2020 | 11 | 0.170 |
Why?
|
Chromosome Aberrations | 4 | 2008 | 62 | 0.170 |
Why?
|
Colon | 3 | 2003 | 136 | 0.170 |
Why?
|
Diagnosis, Differential | 9 | 2018 | 933 | 0.170 |
Why?
|
Polymerase Chain Reaction | 6 | 2016 | 495 | 0.170 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2011 | 12 | 0.160 |
Why?
|
Carcinoma, Endometrioid | 2 | 2011 | 17 | 0.160 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2000 | 168 | 0.160 |
Why?
|
Oncogenes | 2 | 2018 | 66 | 0.160 |
Why?
|
Adenoma | 5 | 2009 | 64 | 0.160 |
Why?
|
Eosinophilia | 3 | 2008 | 29 | 0.160 |
Why?
|
Endometrial Neoplasms | 2 | 2011 | 53 | 0.160 |
Why?
|
Islets of Langerhans Transplantation | 4 | 2007 | 174 | 0.160 |
Why?
|
Mitoxantrone | 1 | 2018 | 16 | 0.160 |
Why?
|
Induction Chemotherapy | 1 | 2018 | 31 | 0.150 |
Why?
|
Carcinoma in Situ | 2 | 2010 | 32 | 0.150 |
Why?
|
Rats, Inbred Lew | 10 | 2009 | 106 | 0.150 |
Why?
|
Carcinoma, Papillary | 2 | 2008 | 35 | 0.150 |
Why?
|
Urothelium | 2 | 2016 | 22 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 6 | 0.150 |
Why?
|
Receptor, ErbB-4 | 1 | 2018 | 9 | 0.150 |
Why?
|
Adenoma, Oxyphilic | 1 | 2018 | 11 | 0.150 |
Why?
|
Heterozygote | 2 | 2016 | 161 | 0.150 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2010 | 106 | 0.150 |
Why?
|
Leukemia | 4 | 2013 | 57 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 3 | 2013 | 673 | 0.140 |
Why?
|
Interleukin Receptor Common gamma Subunit | 2 | 2008 | 78 | 0.140 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2008 | 7 | 0.140 |
Why?
|
Intestinal Neoplasms | 1 | 1997 | 13 | 0.140 |
Why?
|
Skin Neoplasms | 3 | 2014 | 404 | 0.140 |
Why?
|
Predictive Value of Tests | 7 | 2016 | 1025 | 0.140 |
Why?
|
Papillomavirus Infections | 2 | 2011 | 120 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2016 | 5 | 0.140 |
Why?
|
Herpesviridae Infections | 3 | 1996 | 25 | 0.140 |
Why?
|
Rats, Mutant Strains | 4 | 1991 | 10 | 0.130 |
Why?
|
Gene Deletion | 1 | 2018 | 292 | 0.130 |
Why?
|
Histiocytic Sarcoma | 1 | 2016 | 4 | 0.130 |
Why?
|
Hemoglobin C | 1 | 2016 | 2 | 0.130 |
Why?
|
Anemia, Hypochromic | 1 | 2016 | 5 | 0.130 |
Why?
|
Hemoglobins, Abnormal | 1 | 2016 | 6 | 0.130 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2007 | 116 | 0.130 |
Why?
|
B7-H1 Antigen | 1 | 2016 | 54 | 0.130 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 209 | 0.130 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 2 | 1993 | 3 | 0.130 |
Why?
|
Sarcoma | 1 | 2016 | 37 | 0.130 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2016 | 28 | 0.130 |
Why?
|
Burkitt Lymphoma | 2 | 2016 | 57 | 0.130 |
Why?
|
Eukaryotic Initiation Factor-4E | 3 | 2008 | 15 | 0.130 |
Why?
|
Cell Polarity | 3 | 2010 | 109 | 0.120 |
Why?
|
Prostatic Intraepithelial Neoplasia | 2 | 2006 | 4 | 0.120 |
Why?
|
Treatment Failure | 2 | 2013 | 185 | 0.120 |
Why?
|
Adenoma, Villous | 1 | 1995 | 1 | 0.120 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 3 | 2003 | 14 | 0.120 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 3 | 2003 | 15 | 0.120 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2003 | 53 | 0.120 |
Why?
|
Immunophenotyping | 6 | 2016 | 184 | 0.120 |
Why?
|
DNA Damage | 3 | 2016 | 279 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2009 | 193 | 0.120 |
Why?
|
Pneumonia | 2 | 2013 | 281 | 0.120 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2014 | 4 | 0.120 |
Why?
|
Neoplastic Stem Cells | 3 | 2012 | 196 | 0.120 |
Why?
|
Fixatives | 1 | 2014 | 17 | 0.120 |
Why?
|
Cell Adhesion Molecules | 1 | 1995 | 85 | 0.120 |
Why?
|
Salvage Therapy | 2 | 2013 | 72 | 0.110 |
Why?
|
ADP Ribose Transferases | 2 | 1991 | 62 | 0.110 |
Why?
|
Disease Progression | 6 | 2024 | 1122 | 0.110 |
Why?
|
Cytotoxins | 1 | 1994 | 12 | 0.110 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2014 | 25 | 0.110 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 57 | 0.110 |
Why?
|
Dendritic Cells | 2 | 2013 | 507 | 0.110 |
Why?
|
Pathology, Clinical | 1 | 2014 | 21 | 0.110 |
Why?
|
Cholangiocarcinoma | 1 | 2014 | 27 | 0.110 |
Why?
|
Antigens, Surface | 7 | 2002 | 191 | 0.110 |
Why?
|
Antigens, CD34 | 2 | 2011 | 54 | 0.110 |
Why?
|
Lung | 3 | 2008 | 913 | 0.110 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 33 | 0.110 |
Why?
|
Leukocytes, Mononuclear | 2 | 2007 | 238 | 0.110 |
Why?
|
Graft Rejection | 4 | 2007 | 289 | 0.110 |
Why?
|
Histiocytosis, Sinus | 1 | 1993 | 2 | 0.110 |
Why?
|
Mice | 21 | 2016 | 10251 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 5 | 2014 | 396 | 0.100 |
Why?
|
Anemia, Hemolytic | 1 | 2013 | 12 | 0.100 |
Why?
|
Neoplasm Grading | 1 | 2013 | 79 | 0.100 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
Young Adult | 7 | 2018 | 4266 | 0.100 |
Why?
|
Biopsy | 5 | 2016 | 411 | 0.100 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 46 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2013 | 115 | 0.100 |
Why?
|
Skin Transplantation | 4 | 2002 | 155 | 0.100 |
Why?
|
Lymphocytic Choriomeningitis | 4 | 2002 | 53 | 0.100 |
Why?
|
Gastric Mucosa | 2 | 2010 | 51 | 0.100 |
Why?
|
Erythrocytes | 2 | 1987 | 146 | 0.100 |
Why?
|
CD40 Ligand | 6 | 2002 | 156 | 0.100 |
Why?
|
Stomach Neoplasms | 2 | 2010 | 69 | 0.100 |
Why?
|
Human papillomavirus 18 | 1 | 2011 | 4 | 0.100 |
Why?
|
Autoimmunity | 2 | 2006 | 223 | 0.100 |
Why?
|
Immunologic Deficiency Syndromes | 2 | 2013 | 67 | 0.100 |
Why?
|
Adrenal Glands | 1 | 2012 | 32 | 0.100 |
Why?
|
Human papillomavirus 16 | 1 | 2011 | 17 | 0.100 |
Why?
|
Mice, Inbred C57BL | 12 | 2016 | 3220 | 0.100 |
Why?
|
Tumor Virus Infections | 3 | 1997 | 37 | 0.090 |
Why?
|
Disease-Free Survival | 4 | 2014 | 228 | 0.090 |
Why?
|
RNA, Viral | 1 | 2013 | 259 | 0.090 |
Why?
|
Organ Transplantation | 1 | 2012 | 53 | 0.090 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2012 | 143 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2011 | 19 | 0.090 |
Why?
|
Antigens, Neoplasm | 3 | 2008 | 133 | 0.090 |
Why?
|
Graft Survival | 3 | 2002 | 290 | 0.090 |
Why?
|
Mesothelioma | 1 | 2011 | 27 | 0.090 |
Why?
|
Megakaryocytes | 1 | 2011 | 18 | 0.090 |
Why?
|
Peritoneal Neoplasms | 1 | 2011 | 24 | 0.090 |
Why?
|
Immunotherapy, Adoptive | 1 | 2012 | 86 | 0.090 |
Why?
|
Epithelium | 1 | 2011 | 96 | 0.090 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2010 | 4 | 0.090 |
Why?
|
Liver Neoplasms | 1 | 2014 | 277 | 0.090 |
Why?
|
Genes, X-Linked | 1 | 2011 | 19 | 0.090 |
Why?
|
Endopeptidases | 1 | 2011 | 68 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2008 | 188 | 0.090 |
Why?
|
Lymphocyte Depletion | 7 | 2002 | 99 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2011 | 58 | 0.090 |
Why?
|
Meningioma | 1 | 2011 | 59 | 0.090 |
Why?
|
Immunization | 2 | 2009 | 127 | 0.090 |
Why?
|
NADPH Oxidases | 1 | 2011 | 65 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.090 |
Why?
|
Blotting, Western | 4 | 2014 | 583 | 0.090 |
Why?
|
Stomach Diseases | 1 | 2010 | 10 | 0.090 |
Why?
|
Hematopoiesis | 3 | 2008 | 120 | 0.090 |
Why?
|
Time Factors | 9 | 2014 | 3614 | 0.090 |
Why?
|
Palliative Care | 1 | 2013 | 215 | 0.090 |
Why?
|
Immune Tolerance | 3 | 2000 | 172 | 0.090 |
Why?
|
Karyotyping | 6 | 2011 | 44 | 0.090 |
Why?
|
Protein Kinase C | 1 | 2010 | 98 | 0.090 |
Why?
|
Autoimmune Diseases | 3 | 1991 | 220 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2011 | 236 | 0.080 |
Why?
|
Lymphopenia | 2 | 1987 | 35 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2012 | 384 | 0.080 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 5 | 0.080 |
Why?
|
Basophils | 1 | 2009 | 14 | 0.080 |
Why?
|
Survival Rate | 5 | 2011 | 802 | 0.080 |
Why?
|
Adolescent | 7 | 2018 | 5822 | 0.080 |
Why?
|
Homeostasis | 1 | 2012 | 346 | 0.080 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 188 | 0.080 |
Why?
|
Diabetes Insipidus | 2 | 1987 | 2 | 0.080 |
Why?
|
Barrett Esophagus | 1 | 2009 | 30 | 0.080 |
Why?
|
Sepsis | 1 | 2013 | 272 | 0.080 |
Why?
|
CD55 Antigens | 1 | 2008 | 1 | 0.080 |
Why?
|
CD59 Antigens | 1 | 2008 | 2 | 0.080 |
Why?
|
Gene Rearrangement | 4 | 2014 | 38 | 0.080 |
Why?
|
Transforming Growth Factor alpha | 2 | 1999 | 16 | 0.080 |
Why?
|
Glucose | 1 | 2012 | 445 | 0.080 |
Why?
|
X Chromosome | 1 | 1989 | 44 | 0.080 |
Why?
|
Gene Expression Profiling | 2 | 2016 | 716 | 0.080 |
Why?
|
Antigen-Antibody Complex | 2 | 1980 | 51 | 0.080 |
Why?
|
Erythroblasts | 1 | 2008 | 15 | 0.080 |
Why?
|
Lymphatic Diseases | 2 | 1985 | 13 | 0.080 |
Why?
|
Monocytes | 2 | 2008 | 343 | 0.080 |
Why?
|
Tissue Embedding | 1 | 2008 | 3 | 0.080 |
Why?
|
Virus Diseases | 1 | 2009 | 114 | 0.080 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2008 | 19 | 0.080 |
Why?
|
Apoptosis | 5 | 2016 | 1032 | 0.080 |
Why?
|
Erythroid Precursor Cells | 1 | 2008 | 20 | 0.080 |
Why?
|
Sp1 Transcription Factor | 1 | 2008 | 21 | 0.080 |
Why?
|
Lipidoses | 1 | 1988 | 1 | 0.080 |
Why?
|
Langerhans Cells | 1 | 1988 | 11 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 18 | 0.070 |
Why?
|
Viral Matrix Proteins | 3 | 1997 | 47 | 0.070 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 1988 | 16 | 0.070 |
Why?
|
Polyploidy | 1 | 2008 | 11 | 0.070 |
Why?
|
Mosaicism | 1 | 2008 | 26 | 0.070 |
Why?
|
Biopsy, Fine-Needle | 1 | 2008 | 61 | 0.070 |
Why?
|
Antigens | 4 | 2002 | 146 | 0.070 |
Why?
|
Actinin | 1 | 1988 | 9 | 0.070 |
Why?
|
Esophageal Neoplasms | 1 | 2009 | 77 | 0.070 |
Why?
|
Disease Models, Animal | 4 | 2007 | 2046 | 0.070 |
Why?
|
Mice, SCID | 6 | 2008 | 512 | 0.070 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 1988 | 36 | 0.070 |
Why?
|
Concanavalin A | 3 | 1986 | 40 | 0.070 |
Why?
|
Immunoproliferative Disorders | 1 | 1987 | 1 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2008 | 54 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2016 | 2337 | 0.070 |
Why?
|
Neutropenia | 1 | 2008 | 62 | 0.070 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 9 | 0.070 |
Why?
|
Parvovirus B19, Human | 1 | 2007 | 5 | 0.070 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 1 | 2008 | 61 | 0.070 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2007 | 15 | 0.070 |
Why?
|
Tuberculosis | 1 | 2011 | 270 | 0.070 |
Why?
|
Retroperitoneal Fibrosis | 1 | 1987 | 2 | 0.070 |
Why?
|
Severe Combined Immunodeficiency | 2 | 2000 | 53 | 0.070 |
Why?
|
Cytokines | 1 | 1991 | 904 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 1986 | 207 | 0.070 |
Why?
|
Th1 Cells | 1 | 2008 | 174 | 0.070 |
Why?
|
Connective Tissue Diseases | 1 | 1987 | 10 | 0.070 |
Why?
|
Aging | 4 | 1981 | 710 | 0.070 |
Why?
|
Bone and Bones | 1 | 1988 | 137 | 0.070 |
Why?
|
Massachusetts | 5 | 2016 | 2003 | 0.070 |
Why?
|
Lymph Nodes | 6 | 1999 | 214 | 0.070 |
Why?
|
Mediastinum | 1 | 1987 | 27 | 0.070 |
Why?
|
Phagocytosis | 2 | 1987 | 249 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2005 | 294 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 51 | 0.070 |
Why?
|
Anemia, Refractory | 1 | 2006 | 1 | 0.070 |
Why?
|
Thrombocytosis | 1 | 2006 | 3 | 0.070 |
Why?
|
Receptors, Fc | 3 | 1983 | 21 | 0.070 |
Why?
|
Neural Tube Defects | 1 | 2006 | 27 | 0.070 |
Why?
|
Breast | 1 | 2008 | 173 | 0.070 |
Why?
|
Cell Separation | 2 | 1984 | 145 | 0.070 |
Why?
|
ErbB Receptors | 2 | 2014 | 114 | 0.070 |
Why?
|
Liver | 4 | 2006 | 796 | 0.070 |
Why?
|
Neoplasms, Multiple Primary | 2 | 1993 | 29 | 0.070 |
Why?
|
Repressor Proteins | 2 | 2024 | 332 | 0.060 |
Why?
|
Translocation, Genetic | 3 | 2016 | 63 | 0.060 |
Why?
|
Blood Transfusion | 3 | 2001 | 150 | 0.060 |
Why?
|
Lymphocyte Activation | 7 | 2008 | 743 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2016 | 1561 | 0.060 |
Why?
|
G(M2) Ganglioside | 1 | 2005 | 9 | 0.060 |
Why?
|
Jejunal Neoplasms | 1 | 1985 | 4 | 0.060 |
Why?
|
DNA, Viral | 2 | 2005 | 223 | 0.060 |
Why?
|
Mice, Inbred NOD | 5 | 2008 | 516 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2011 | 250 | 0.060 |
Why?
|
Carcinoma, Small Cell | 1 | 2005 | 21 | 0.060 |
Why?
|
Transplantation, Heterologous | 2 | 2008 | 223 | 0.060 |
Why?
|
Lymphoma, T-Cell | 2 | 1998 | 22 | 0.060 |
Why?
|
Primary Myelofibrosis | 1 | 1985 | 10 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2012 | 328 | 0.060 |
Why?
|
Immunization, Passive | 1 | 2005 | 99 | 0.060 |
Why?
|
Dendrites | 1 | 1985 | 56 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2018 | 5283 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2006 | 631 | 0.060 |
Why?
|
Papillomaviridae | 1 | 2005 | 58 | 0.060 |
Why?
|
Rats, Inbred BN | 3 | 1981 | 25 | 0.060 |
Why?
|
Receptors, Antigen | 2 | 1984 | 7 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2016 | 6071 | 0.060 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.060 |
Why?
|
Diabetes Mellitus | 2 | 2007 | 515 | 0.060 |
Why?
|
Thymoma | 1 | 1984 | 11 | 0.060 |
Why?
|
Thymus Neoplasms | 1 | 1984 | 21 | 0.060 |
Why?
|
Endocytosis | 2 | 1982 | 148 | 0.060 |
Why?
|
Cell Differentiation | 2 | 2008 | 1298 | 0.060 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.050 |
Why?
|
Gene Expression | 3 | 2007 | 808 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 4 | 1990 | 145 | 0.050 |
Why?
|
Nevus, Pigmented | 1 | 2003 | 19 | 0.050 |
Why?
|
Androgen Antagonists | 1 | 2003 | 20 | 0.050 |
Why?
|
Receptors, Androgen | 1 | 2003 | 27 | 0.050 |
Why?
|
RNA, Messenger | 5 | 2005 | 1464 | 0.050 |
Why?
|
Poly I-C | 4 | 2009 | 76 | 0.050 |
Why?
|
Inflammation | 4 | 1994 | 1094 | 0.050 |
Why?
|
Cell Proliferation | 3 | 2011 | 940 | 0.050 |
Why?
|
Trifluoperazine | 1 | 1982 | 3 | 0.050 |
Why?
|
Prostatic Hyperplasia | 1 | 2002 | 8 | 0.050 |
Why?
|
Infant | 4 | 2016 | 1486 | 0.050 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2003 | 128 | 0.050 |
Why?
|
Phosphorylation | 2 | 2016 | 882 | 0.050 |
Why?
|
Lymphocytic choriomeningitis virus | 2 | 2000 | 88 | 0.050 |
Why?
|
Bone Marrow Examination | 3 | 2014 | 8 | 0.050 |
Why?
|
Transplantation Tolerance | 1 | 2002 | 65 | 0.050 |
Why?
|
DNA Methylation | 2 | 2014 | 271 | 0.050 |
Why?
|
Germinoma | 1 | 2001 | 1 | 0.050 |
Why?
|
Splenic Neoplasms | 1 | 1981 | 8 | 0.050 |
Why?
|
Eye Neoplasms | 1 | 2001 | 17 | 0.050 |
Why?
|
Retinoblastoma | 1 | 2001 | 27 | 0.050 |
Why?
|
Leiomyosarcoma | 1 | 2001 | 9 | 0.050 |
Why?
|
Fibroblasts | 3 | 2016 | 377 | 0.050 |
Why?
|
Testicular Neoplasms | 1 | 2001 | 32 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2016 | 1204 | 0.050 |
Why?
|
CD8 Antigens | 3 | 2002 | 53 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2001 | 43 | 0.050 |
Why?
|
Vincristine | 2 | 2014 | 25 | 0.050 |
Why?
|
Cyclophosphamide | 2 | 2014 | 75 | 0.040 |
Why?
|
HLA Antigens | 1 | 1981 | 61 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 6 | 1998 | 216 | 0.040 |
Why?
|
Prednisone | 2 | 2014 | 85 | 0.040 |
Why?
|
ras Proteins | 2 | 2014 | 77 | 0.040 |
Why?
|
DNA, Neoplasm | 3 | 2003 | 52 | 0.040 |
Why?
|
Mice, Inbred BALB C | 6 | 2002 | 868 | 0.040 |
Why?
|
Doxorubicin | 2 | 2014 | 97 | 0.040 |
Why?
|
NF-kappa B | 2 | 2008 | 458 | 0.040 |
Why?
|
Cohort Studies | 2 | 2016 | 2372 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2012 | 25 | 0.040 |
Why?
|
Transplantation Chimera | 1 | 2000 | 39 | 0.040 |
Why?
|
Molecular Weight | 3 | 2002 | 184 | 0.040 |
Why?
|
Transcription Factors | 1 | 2008 | 1470 | 0.040 |
Why?
|
Blood Platelets | 1 | 2001 | 92 | 0.040 |
Why?
|
Syndrome | 3 | 1990 | 170 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2001 | 620 | 0.040 |
Why?
|
Cell Count | 2 | 2011 | 127 | 0.040 |
Why?
|
Biomarkers | 3 | 2010 | 1305 | 0.040 |
Why?
|
Microspheres | 3 | 2005 | 54 | 0.040 |
Why?
|
Antigens, CD | 3 | 2007 | 341 | 0.040 |
Why?
|
Age Factors | 2 | 2018 | 1504 | 0.040 |
Why?
|
Transplantation, Homologous | 1 | 2000 | 244 | 0.040 |
Why?
|
Anesthetics, Local | 1 | 1980 | 68 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2008 | 1118 | 0.040 |
Why?
|
Child | 6 | 2006 | 4173 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Direct | 2 | 2009 | 9 | 0.040 |
Why?
|
Infectious Mononucleosis | 3 | 1989 | 33 | 0.040 |
Why?
|
Cervix Uteri | 2 | 2011 | 56 | 0.040 |
Why?
|
Gastrointestinal Neoplasms | 1 | 1999 | 31 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 4 | 2001 | 1525 | 0.040 |
Why?
|
Rituximab | 2 | 2012 | 80 | 0.040 |
Why?
|
Colchicine | 5 | 1987 | 27 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 1996 | 98 | 0.040 |
Why?
|
Mice, Knockout | 3 | 2012 | 1985 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 527 | 0.040 |
Why?
|
Transplantation Conditioning | 3 | 2008 | 98 | 0.040 |
Why?
|
Keratins | 3 | 2004 | 30 | 0.040 |
Why?
|
Reference Values | 1 | 1999 | 326 | 0.040 |
Why?
|
Remission Induction | 1 | 2018 | 137 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 75 | 0.040 |
Why?
|
Immunity, Innate | 5 | 2000 | 765 | 0.040 |
Why?
|
Hypohidrosis | 1 | 1998 | 3 | 0.040 |
Why?
|
Cytomegalovirus Infections | 3 | 2009 | 66 | 0.040 |
Why?
|
Centrosome | 1 | 1998 | 71 | 0.040 |
Why?
|
Alopecia | 1 | 1998 | 25 | 0.040 |
Why?
|
Cell Transformation, Viral | 2 | 1996 | 15 | 0.040 |
Why?
|
Ileal Neoplasms | 1 | 1997 | 3 | 0.040 |
Why?
|
Sweat Gland Neoplasms | 1 | 1998 | 20 | 0.040 |
Why?
|
Pruritus | 1 | 1998 | 29 | 0.040 |
Why?
|
Sjogren's Syndrome | 1 | 1998 | 24 | 0.040 |
Why?
|
Cells, Cultured | 5 | 1995 | 2089 | 0.040 |
Why?
|
Child, Preschool | 3 | 2010 | 1782 | 0.040 |
Why?
|
Melanocytes | 2 | 2012 | 78 | 0.040 |
Why?
|
Carcinoid Tumor | 1 | 1997 | 12 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 70 | 0.040 |
Why?
|
Cricetinae | 2 | 2011 | 365 | 0.040 |
Why?
|
Immunologic Techniques | 1 | 1977 | 12 | 0.040 |
Why?
|
Tumor Cells, Cultured | 3 | 1998 | 450 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Indirect | 2 | 2008 | 34 | 0.040 |
Why?
|
Cell Line | 10 | 1993 | 1968 | 0.040 |
Why?
|
Radiography, Abdominal | 1 | 1997 | 27 | 0.040 |
Why?
|
Leukocyte Count | 2 | 1995 | 97 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2008 | 583 | 0.030 |
Why?
|
History, 17th Century | 1 | 2016 | 5 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 1997 | 137 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 355 | 0.030 |
Why?
|
Janus Kinase 2 | 2 | 2006 | 14 | 0.030 |
Why?
|
Tetrasomy | 1 | 2016 | 3 | 0.030 |
Why?
|
Proteins | 1 | 2002 | 730 | 0.030 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 1996 | 1 | 0.030 |
Why?
|
Tuberculosis, Miliary | 1 | 1996 | 3 | 0.030 |
Why?
|
Antigens, Viral | 2 | 1987 | 129 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2011 | 902 | 0.030 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1996 | 7 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 53 | 0.030 |
Why?
|
Exons | 1 | 2016 | 190 | 0.030 |
Why?
|
HeLa Cells | 3 | 2011 | 523 | 0.030 |
Why?
|
Bronchi | 1 | 1996 | 82 | 0.030 |
Why?
|
Lipopolysaccharides | 2 | 2012 | 626 | 0.030 |
Why?
|
Intestine, Large | 1 | 1995 | 5 | 0.030 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 140 | 0.030 |
Why?
|
Observer Variation | 1 | 2016 | 205 | 0.030 |
Why?
|
In Vitro Techniques | 4 | 1990 | 469 | 0.030 |
Why?
|
DNA | 2 | 2006 | 806 | 0.030 |
Why?
|
Alleles | 1 | 2016 | 410 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 256 | 0.030 |
Why?
|
Cell Fusion | 1 | 1995 | 36 | 0.030 |
Why?
|
CD5 Antigens | 2 | 1993 | 18 | 0.030 |
Why?
|
Lymphoid Tissue | 3 | 2002 | 54 | 0.030 |
Why?
|
Prospective Studies | 3 | 2009 | 3065 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 1997 | 312 | 0.030 |
Why?
|
Colitis, Ulcerative | 1 | 1995 | 71 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2014 | 21 | 0.030 |
Why?
|
Alcohols | 1 | 2014 | 12 | 0.030 |
Why?
|
Lipids | 2 | 2012 | 300 | 0.030 |
Why?
|
Formaldehyde | 1 | 2014 | 32 | 0.030 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 1 | 1994 | 1 | 0.030 |
Why?
|
Syndecan-1 | 1 | 2014 | 7 | 0.030 |
Why?
|
Acute Disease | 4 | 1995 | 659 | 0.030 |
Why?
|
Signal Transduction | 2 | 2016 | 2888 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2014 | 44 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1994 | 27 | 0.030 |
Why?
|
Antibodies, Anti-Idiotypic | 2 | 1984 | 33 | 0.030 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 105 | 0.030 |
Why?
|
Papanicolaou Test | 1 | 2014 | 42 | 0.030 |
Why?
|
Thy-1 Antigens | 2 | 1984 | 21 | 0.030 |
Why?
|
Polyomavirus | 1 | 1994 | 24 | 0.030 |
Why?
|
Crohn Disease | 1 | 1995 | 105 | 0.030 |
Why?
|
Bile Duct Neoplasms | 1 | 2014 | 42 | 0.030 |
Why?
|
Solubility | 2 | 1984 | 176 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 1995 | 130 | 0.030 |
Why?
|
Aneuploidy | 1 | 1994 | 40 | 0.030 |
Why?
|
Polyomavirus Infections | 1 | 1994 | 46 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1994 | 213 | 0.030 |
Why?
|
Automation | 2 | 2003 | 51 | 0.030 |
Why?
|
Macrophage Activation Syndrome | 1 | 2013 | 5 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 191 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 2 | 2003 | 42 | 0.030 |
Why?
|
Biotechnology | 2 | 2003 | 42 | 0.030 |
Why?
|
Bromodeoxyuridine | 1 | 1993 | 40 | 0.030 |
Why?
|
Deoxyribonuclease I | 1 | 1993 | 40 | 0.030 |
Why?
|
Tandem Repeat Sequences | 1 | 2012 | 26 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 1976 | 322 | 0.030 |
Why?
|
Collagen | 2 | 2005 | 115 | 0.030 |
Why?
|
Gene Duplication | 1 | 2012 | 31 | 0.030 |
Why?
|
CpG Islands | 1 | 2014 | 211 | 0.030 |
Why?
|
Cytarabine | 1 | 2012 | 32 | 0.030 |
Why?
|
Cytochalasins | 3 | 1981 | 4 | 0.030 |
Why?
|
Eosinophils | 1 | 1993 | 52 | 0.030 |
Why?
|
Cell Division | 3 | 2003 | 443 | 0.030 |
Why?
|
Plasma Cells | 1 | 1993 | 49 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2012 | 21 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1993 | 68 | 0.020 |
Why?
|
Mice, 129 Strain | 1 | 2012 | 37 | 0.020 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 42 | 0.020 |
Why?
|
Receptors, Concanavalin A | 2 | 1982 | 2 | 0.020 |
Why?
|
Serine | 1 | 2012 | 83 | 0.020 |
Why?
|
Cerebellar Neoplasms | 1 | 1992 | 9 | 0.020 |
Why?
|
Protein Stability | 1 | 2012 | 85 | 0.020 |
Why?
|
Point Mutation | 3 | 1997 | 160 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2003 | 297 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2011 | 23 | 0.020 |
Why?
|
Fasting | 1 | 2012 | 48 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 2 | 1984 | 179 | 0.020 |
Why?
|
Macrophages, Peritoneal | 1 | 2012 | 73 | 0.020 |
Why?
|
Intestine, Small | 1 | 2012 | 76 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2012 | 96 | 0.020 |
Why?
|
Membrane Fluidity | 2 | 1982 | 14 | 0.020 |
Why?
|
Pleura | 1 | 2011 | 13 | 0.020 |
Why?
|
Autoantibodies | 3 | 1987 | 172 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 358 | 0.020 |
Why?
|
Mice, Inbred CBA | 2 | 2002 | 83 | 0.020 |
Why?
|
Peritoneum | 1 | 2011 | 27 | 0.020 |
Why?
|
Chronic Disease | 2 | 2008 | 716 | 0.020 |
Why?
|
Adiposity | 1 | 2012 | 74 | 0.020 |
Why?
|
Endometrium | 1 | 2011 | 28 | 0.020 |
Why?
|
Thymus Gland | 1 | 2012 | 229 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2012 | 172 | 0.020 |
Why?
|
Virus Physiological Phenomena | 1 | 1991 | 7 | 0.020 |
Why?
|
Frozen Sections | 2 | 2003 | 10 | 0.020 |
Why?
|
Hyperplasia | 1 | 2011 | 84 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1991 | 99 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1991 | 148 | 0.020 |
Why?
|
Hypoglycemia | 1 | 2012 | 66 | 0.020 |
Why?
|
California | 1 | 2011 | 159 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2014 | 650 | 0.020 |
Why?
|
NADPH Oxidase 2 | 1 | 2011 | 35 | 0.020 |
Why?
|
Qa-SNARE Proteins | 1 | 2010 | 18 | 0.020 |
Why?
|
Dietary Fats | 1 | 2012 | 173 | 0.020 |
Why?
|
Antigens, Differentiation | 1 | 1991 | 137 | 0.020 |
Why?
|
Perforin | 1 | 2010 | 30 | 0.020 |
Why?
|
Gastritis | 1 | 2010 | 16 | 0.020 |
Why?
|
Contractile Proteins | 2 | 1980 | 14 | 0.020 |
Why?
|
Cricetulus | 1 | 2011 | 99 | 0.020 |
Why?
|
Postoperative Complications | 1 | 1997 | 1202 | 0.020 |
Why?
|
Goats | 2 | 1981 | 9 | 0.020 |
Why?
|
Fatty Acids | 1 | 2012 | 190 | 0.020 |
Why?
|
CHO Cells | 1 | 2011 | 189 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1991 | 156 | 0.020 |
Why?
|
Tryptophan | 1 | 1990 | 54 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 331 | 0.020 |
Why?
|
Muscular Diseases | 1 | 1990 | 46 | 0.020 |
Why?
|
Hemocyanins | 2 | 1980 | 22 | 0.020 |
Why?
|
Parvoviridae Infections | 1 | 1990 | 23 | 0.020 |
Why?
|
Body Weight | 1 | 2012 | 368 | 0.020 |
Why?
|
Ligands | 2 | 2000 | 410 | 0.020 |
Why?
|
Enterovirus Infections | 1 | 2009 | 11 | 0.020 |
Why?
|
Base Sequence | 3 | 2003 | 1300 | 0.020 |
Why?
|
Enterovirus B, Human | 1 | 2009 | 17 | 0.020 |
Why?
|
Disease Susceptibility | 2 | 1987 | 157 | 0.020 |
Why?
|
Cell Movement | 1 | 2011 | 428 | 0.020 |
Why?
|
Interleukin-6 | 1 | 1991 | 308 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2011 | 299 | 0.020 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2009 | 9 | 0.020 |
Why?
|
Cisplatin | 1 | 1990 | 119 | 0.020 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2009 | 8 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2009 | 19 | 0.020 |
Why?
|
Pancreas | 1 | 2010 | 147 | 0.020 |
Why?
|
Mucous Membrane | 1 | 2009 | 20 | 0.020 |
Why?
|
Vaccinia virus | 1 | 2009 | 70 | 0.020 |
Why?
|
Risk Factors | 2 | 2012 | 4982 | 0.020 |
Why?
|
Protein Biosynthesis | 2 | 2002 | 297 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 674 | 0.020 |
Why?
|
Esophagus | 1 | 2009 | 50 | 0.020 |
Why?
|
United States | 2 | 2014 | 7385 | 0.020 |
Why?
|
Genetic Linkage | 1 | 1989 | 93 | 0.020 |
Why?
|
Mitosis | 2 | 2008 | 208 | 0.020 |
Why?
|
Models, Animal | 1 | 2009 | 221 | 0.020 |
Why?
|
Antibodies, Viral | 2 | 1990 | 291 | 0.020 |
Why?
|
Lymphopoiesis | 1 | 2008 | 27 | 0.020 |
Why?
|
Ultrasonography | 1 | 1991 | 459 | 0.020 |
Why?
|
Cell Cycle | 2 | 1990 | 382 | 0.020 |
Why?
|
Histological Techniques | 1 | 2008 | 18 | 0.020 |
Why?
|
Sclerosis | 1 | 1988 | 7 | 0.020 |
Why?
|
Leukopenia | 1 | 2008 | 16 | 0.020 |
Why?
|
RNA Interference | 1 | 2011 | 590 | 0.020 |
Why?
|
Isoelectric Point | 1 | 1988 | 12 | 0.020 |
Why?
|
Actins | 2 | 2001 | 258 | 0.020 |
Why?
|
Chemical Precipitation | 1 | 1988 | 11 | 0.020 |
Why?
|
Genes, Dominant | 1 | 2008 | 55 | 0.020 |
Why?
|
Paraproteinemias | 1 | 2008 | 17 | 0.020 |
Why?
|
Risk | 1 | 2008 | 364 | 0.020 |
Why?
|
Granulocytes | 1 | 2008 | 69 | 0.020 |
Why?
|
Histocytochemistry | 2 | 1986 | 47 | 0.020 |
Why?
|
Insulin | 1 | 2012 | 674 | 0.020 |
Why?
|
Histiocytes | 1 | 1987 | 5 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2008 | 95 | 0.020 |
Why?
|
Epitopes | 2 | 2005 | 285 | 0.020 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 1987 | 29 | 0.020 |
Why?
|
Radiation Dosage | 1 | 1988 | 131 | 0.020 |
Why?
|
Pedigree | 1 | 2008 | 183 | 0.020 |
Why?
|
Mutagenesis | 1 | 2008 | 129 | 0.020 |
Why?
|
Pancytopenia | 1 | 1987 | 7 | 0.020 |
Why?
|
Intermediate Filament Proteins | 1 | 1987 | 19 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2008 | 178 | 0.020 |
Why?
|
Intermediate Filaments | 1 | 1986 | 10 | 0.020 |
Why?
|
Age Distribution | 1 | 2007 | 249 | 0.020 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1986 | 1 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2003 | 1949 | 0.020 |
Why?
|
Sequence Deletion | 2 | 1997 | 112 | 0.020 |
Why?
|
Cell Survival | 3 | 1990 | 559 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2006 | 23 | 0.020 |
Why?
|
Fibrosis | 1 | 1987 | 153 | 0.020 |
Why?
|
Risk Assessment | 2 | 2003 | 1920 | 0.020 |
Why?
|
Radiography | 1 | 1988 | 516 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2008 | 688 | 0.020 |
Why?
|
Leukemia, Lymphoid | 1 | 1985 | 11 | 0.020 |
Why?
|
Orchiectomy | 1 | 2005 | 28 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 1986 | 169 | 0.020 |
Why?
|
Mice, Inbred AKR | 1 | 2005 | 12 | 0.020 |
Why?
|
Interleukin-2 | 1 | 1986 | 164 | 0.020 |
Why?
|
S100 Proteins | 1 | 1985 | 19 | 0.020 |
Why?
|
Avian Leukosis Virus | 1 | 1985 | 3 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2009 | 606 | 0.020 |
Why?
|
Kinetics | 2 | 2002 | 750 | 0.020 |
Why?
|
Jurkat Cells | 1 | 2005 | 103 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2005 | 100 | 0.020 |
Why?
|
Arthritis | 1 | 2005 | 49 | 0.020 |
Why?
|
Pituitary Gland, Posterior | 1 | 1985 | 17 | 0.020 |
Why?
|
Hemangiosarcoma | 1 | 1985 | 23 | 0.020 |
Why?
|
Pituitary Gland | 2 | 1987 | 51 | 0.010 |
Why?
|
Skin | 3 | 1990 | 357 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 1986 | 276 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2008 | 653 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2005 | 115 | 0.010 |
Why?
|
Liposomes | 1 | 1984 | 100 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2008 | 1283 | 0.010 |
Why?
|
HIV Infections | 1 | 2011 | 912 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 1984 | 99 | 0.010 |
Why?
|
Incidence | 1 | 2007 | 1236 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 1990 | 52 | 0.010 |
Why?
|
Octoxynol | 1 | 1983 | 11 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 1984 | 90 | 0.010 |
Why?
|
Hepatitis, Viral, Animal | 1 | 1983 | 1 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2003 | 32 | 0.010 |
Why?
|
DNA Probes | 1 | 2003 | 35 | 0.010 |
Why?
|
Transduction, Genetic | 1 | 1985 | 228 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 1479 | 0.010 |
Why?
|
Prostatectomy | 1 | 2003 | 64 | 0.010 |
Why?
|
Probability | 1 | 2003 | 166 | 0.010 |
Why?
|
Diffusion | 1 | 1983 | 82 | 0.010 |
Why?
|
Genotype | 1 | 2005 | 617 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2003 | 241 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 1992 | 2059 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2002 | 8 | 0.010 |
Why?
|
Injections, Intraperitoneal | 1 | 2002 | 46 | 0.010 |
Why?
|
Radiation Chimera | 1 | 2002 | 57 | 0.010 |
Why?
|
Pregnancy | 1 | 2009 | 2202 | 0.010 |
Why?
|
Antibodies, Blocking | 1 | 2002 | 40 | 0.010 |
Why?
|
Antigens, Ly | 1 | 2002 | 42 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 1983 | 165 | 0.010 |
Why?
|
Equipment Design | 1 | 2003 | 329 | 0.010 |
Why?
|
Lectins, C-Type | 1 | 2002 | 77 | 0.010 |
Why?
|
Contrast Media | 1 | 1984 | 408 | 0.010 |
Why?
|
Desmin | 1 | 2001 | 5 | 0.010 |
Why?
|
Cyclin D1 | 1 | 2001 | 19 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 2001 | 37 | 0.010 |
Why?
|
Hematuria | 1 | 2001 | 19 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 119 | 0.010 |
Why?
|
Cystectomy | 1 | 2001 | 24 | 0.010 |
Why?
|
Ovariectomy | 1 | 2001 | 96 | 0.010 |
Why?
|
Viral Load | 1 | 2002 | 219 | 0.010 |
Why?
|
Immunoglobulin gamma-Chains | 1 | 1981 | 5 | 0.010 |
Why?
|
Immunoglobulin mu-Chains | 1 | 1981 | 13 | 0.010 |
Why?
|
Sulfur Radioisotopes | 1 | 2001 | 12 | 0.010 |
Why?
|
beta 2-Microglobulin | 1 | 1981 | 48 | 0.010 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2001 | 25 | 0.010 |
Why?
|
Platelet Aggregation | 1 | 2001 | 23 | 0.010 |
Why?
|
Hysterectomy | 1 | 2001 | 65 | 0.010 |
Why?
|
Cell Lineage | 1 | 2002 | 257 | 0.010 |
Why?
|
Adenosine Diphosphate | 1 | 2001 | 40 | 0.010 |
Why?
|
Sarcoma, Experimental | 1 | 1980 | 6 | 0.010 |
Why?
|
Binding Sites, Antibody | 1 | 1980 | 23 | 0.010 |
Why?
|
Fluoresceins | 1 | 1980 | 29 | 0.010 |
Why?
|
Peritoneal Cavity | 1 | 2000 | 31 | 0.010 |
Why?
|
Serum Albumin, Bovine | 1 | 1980 | 34 | 0.010 |
Why?
|
Clonal Anergy | 1 | 2000 | 23 | 0.010 |
Why?
|
Survivors | 1 | 2001 | 149 | 0.010 |
Why?
|
Chlorpromazine | 1 | 1980 | 7 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2000 | 98 | 0.010 |
Why?
|
CD40 Antigens | 1 | 2000 | 61 | 0.010 |
Why?
|
Adrenal Cortex | 1 | 1980 | 3 | 0.010 |
Why?
|
Interferon Inducers | 1 | 2000 | 11 | 0.010 |
Why?
|
Leukocyte Transfusion | 1 | 2000 | 16 | 0.010 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2000 | 43 | 0.010 |
Why?
|
Lidocaine | 1 | 1980 | 30 | 0.010 |
Why?
|
Pichinde virus | 1 | 2000 | 20 | 0.010 |
Why?
|
Antibodies | 1 | 2001 | 179 | 0.010 |
Why?
|
Interphase | 1 | 2000 | 68 | 0.010 |
Why?
|
Adoptive Transfer | 1 | 2000 | 147 | 0.010 |
Why?
|
Amino Acids | 1 | 2001 | 140 | 0.010 |
Why?
|
Cattle | 1 | 1980 | 304 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2003 | 1051 | 0.010 |
Why?
|
Antigen-Presenting Cells | 1 | 2000 | 176 | 0.010 |
Why?
|
Thymectomy | 1 | 1999 | 34 | 0.010 |
Why?
|
Hyperglycemia | 1 | 2000 | 98 | 0.010 |
Why?
|
Rabbits | 1 | 1979 | 322 | 0.010 |
Why?
|
Protein Isoforms | 1 | 1999 | 192 | 0.010 |
Why?
|
Carbenicillin | 1 | 1978 | 3 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1999 | 123 | 0.010 |
Why?
|
Nephritis, Interstitial | 1 | 1978 | 14 | 0.010 |
Why?
|
Tissue Donors | 1 | 1999 | 143 | 0.010 |
Why?
|
Recurrence | 1 | 2000 | 602 | 0.010 |
Why?
|
Myocardium | 1 | 1980 | 264 | 0.010 |
Why?
|
Immunotoxins | 1 | 1997 | 6 | 0.010 |
Why?
|
Factor VIII | 1 | 1997 | 31 | 0.010 |
Why?
|
Glomerulonephritis, IGA | 1 | 1997 | 7 | 0.010 |
Why?
|
Virus Latency | 1 | 1997 | 29 | 0.010 |
Why?
|
Interferons | 2 | 1991 | 61 | 0.010 |
Why?
|
Haplorhini | 1 | 1977 | 14 | 0.010 |
Why?
|
Living Donors | 1 | 1997 | 71 | 0.010 |
Why?
|
Lung Diseases | 1 | 1998 | 170 | 0.010 |
Why?
|
Sheep | 1 | 1977 | 169 | 0.010 |
Why?
|
Cytochalasin D | 3 | 1981 | 18 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 1997 | 234 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1979 | 445 | 0.010 |
Why?
|
Cross Reactions | 2 | 1987 | 127 | 0.010 |
Why?
|
Synovial Fluid | 1 | 1976 | 29 | 0.010 |
Why?
|
Rosette Formation | 2 | 1986 | 12 | 0.010 |
Why?
|
HIV Seronegativity | 1 | 1996 | 18 | 0.010 |
Why?
|
Gene Expression Regulation, Viral | 1 | 1996 | 46 | 0.010 |
Why?
|
Half-Life | 1 | 1996 | 75 | 0.010 |
Why?
|
Glomerulonephritis | 1 | 1976 | 31 | 0.010 |
Why?
|
Complement System Proteins | 1 | 1976 | 114 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2000 | 648 | 0.010 |
Why?
|
Selection, Genetic | 1 | 1996 | 71 | 0.010 |
Why?
|
Models, Biological | 1 | 2001 | 1140 | 0.010 |
Why?
|
Genetic Variation | 1 | 1997 | 357 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1996 | 288 | 0.010 |
Why?
|
Antigens, Bacterial | 1 | 1976 | 200 | 0.010 |
Why?
|
Staphylococcus aureus | 1 | 1976 | 163 | 0.010 |
Why?
|
Regeneration | 1 | 1995 | 93 | 0.010 |
Why?
|
Down-Regulation | 1 | 1995 | 305 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 1996 | 656 | 0.010 |
Why?
|
Cell Death | 1 | 1995 | 271 | 0.010 |
Why?
|
Cholesterol | 1 | 1995 | 252 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1993 | 52 | 0.010 |
Why?
|
Formamides | 1 | 1993 | 1 | 0.010 |
Why?
|
Exonucleases | 1 | 1993 | 4 | 0.010 |
Why?
|
Single-Strand Specific DNA and RNA Endonucleases | 1 | 1993 | 5 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 1996 | 305 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 1552 | 0.010 |
Why?
|
Endonucleases | 1 | 1993 | 80 | 0.010 |
Why?
|
Causality | 1 | 1991 | 57 | 0.010 |
Why?
|
Self Medication | 1 | 1990 | 14 | 0.010 |
Why?
|
Rats, Inbred WF | 1 | 1990 | 56 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1990 | 25 | 0.010 |
Why?
|
Parvoviridae | 1 | 1990 | 5 | 0.010 |
Why?
|
Gamma Rays | 1 | 1990 | 31 | 0.010 |
Why?
|
Clone Cells | 1 | 1990 | 106 | 0.010 |
Why?
|
Platinum | 1 | 1990 | 21 | 0.010 |
Why?
|
Viruses | 1 | 1991 | 78 | 0.010 |
Why?
|
Glutathione | 1 | 1990 | 54 | 0.010 |
Why?
|
Sulfhydryl Compounds | 1 | 1990 | 48 | 0.010 |
Why?
|
Species Specificity | 1 | 1990 | 328 | 0.010 |
Why?
|
Muscles | 1 | 1990 | 173 | 0.010 |
Why?
|
Drug Resistance | 1 | 1990 | 95 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 445 | 0.000 |
Why?
|
Phosphonoacetic Acid | 1 | 1987 | 1 | 0.000 |
Why?
|
Pituitary Neoplasms | 1 | 1987 | 21 | 0.000 |
Why?
|
Cytochalasin B | 1 | 1987 | 23 | 0.000 |
Why?
|
Vimentin | 1 | 1987 | 18 | 0.000 |
Why?
|
Colony-Stimulating Factors | 1 | 1986 | 5 | 0.000 |
Why?
|
Interleukin-3 | 1 | 1986 | 21 | 0.000 |
Why?
|
Growth Substances | 1 | 1986 | 34 | 0.000 |
Why?
|
X-Rays | 1 | 1986 | 45 | 0.000 |
Why?
|
Lymphokines | 1 | 1986 | 65 | 0.000 |
Why?
|
Avian Leukosis | 1 | 1985 | 1 | 0.000 |
Why?
|
Chickens | 1 | 1985 | 89 | 0.000 |
Why?
|
Mitogens | 1 | 1984 | 10 | 0.000 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1986 | 281 | 0.000 |
Why?
|
Leukemia, Experimental | 1 | 1984 | 19 | 0.000 |
Why?
|
Metrizamide | 1 | 1984 | 4 | 0.000 |
Why?
|
Diatrizoate Meglumine | 1 | 1984 | 4 | 0.000 |
Why?
|
Diatrizoate | 1 | 1984 | 4 | 0.000 |
Why?
|
Iothalamate Meglumine | 1 | 1984 | 2 | 0.000 |
Why?
|
Triiodobenzoic Acids | 1 | 1984 | 11 | 0.000 |
Why?
|
Thyroiditis | 1 | 1984 | 11 | 0.000 |
Why?
|
Drug Combinations | 1 | 1984 | 146 | 0.000 |
Why?
|
Mice, Mutant Strains | 1 | 1984 | 297 | 0.000 |
Why?
|
Vaccinia | 1 | 1983 | 31 | 0.000 |
Why?
|
Pancreatitis | 1 | 1984 | 95 | 0.000 |
Why?
|
Mice, Inbred C3H | 1 | 1983 | 173 | 0.000 |
Why?
|
Isoantigens | 1 | 1981 | 71 | 0.000 |
Why?
|
Transplantation, Isogeneic | 1 | 1980 | 8 | 0.000 |
Why?
|
Neoplasms, Experimental | 1 | 1980 | 75 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 1987 | 1547 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1980 | 247 | 0.000 |
Why?
|
Receptors, Immunologic | 1 | 1980 | 176 | 0.000 |
Why?
|
Microscopy, Fluorescence | 1 | 1981 | 390 | 0.000 |
Why?
|
Microtubules | 1 | 1980 | 210 | 0.000 |
Why?
|
Kidney Glomerulus | 1 | 1976 | 21 | 0.000 |
Why?
|
Kidney | 1 | 1978 | 416 | 0.000 |
Why?
|
Endocarditis, Bacterial | 1 | 1976 | 31 | 0.000 |
Why?
|